EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers

Table 1 Therapeutic targets being explored in ARID1A mutated cancers

EZH-2	Epigenetic synthetic lethality, promotion of apoptosis	GSK126	[33, 34]
EZH-2	PIK3IP1 mediated inhibition of PI3K/AKT pathway	GSK126	[33, 34]
mTOR	Inhibition of downstream regulator of PI3K/AKT pathway	Temsirolimus	[35, 36]
		Ridaforolimuus
		Everolimus
		AP23573
TP53	Stabilization of wild-type p53 to overcome ARID1A loss, resume tumor suppressor function	Nutlin 3	[13, 37]
PI3K/AKT	Inhibit upregulated AKT phosphorylation caused by concurrent mutations	Sorafenib	[38, 39]
		Copanlisib	[36]
		BKM120
		XL147
BRCA	Enhance DNA-damaging effects of platinum chemotherapies EZH2 modulated function of BRCA1		[40, 41]
ARID1B	Inhibition of residual AWI/SNF complex to suppress cell growth		[42, 43]
Anti-IL6	Inhibit inflammatory microenvironment and escape from anti-tumor immune response		[44]

ISSN: 2053-6844